BFA
GLMD icon

BlackRock Fund Advisors’s Galmed Pharmaceuticals GLMD Stock Holding History

BlackRock Fund Advisors’s Portfolio GLMD Stock Details GLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-5
Closed -$7K – 4330
2015
Q4 		$7K Buy
+5
New +$7.98K ﹤0.01% 4069

Other funds holding GLMD

6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
SKK
Shepherd Kaplan Krochuk Boston, Massachusetts $119M AUM 8.32% 1-Year Est. Return
MC
Menta Capital San Francisco, California $236M AUM 6.6% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
CA
CapWealth Advisors Franklin, Tennessee $1.35B AUM 34.16% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
CAD
Craig A. Drill $24.4M AUM 13.42% 1-Year Est. Return

BlackRock Fund Advisors's GLMD Position: Q1 2016 in Review

BlackRock Fund Advisors sold out of Galmed Pharmaceuticals (GLMD) in Q1 2016, closing a stake of 5 shares — an estimated $7K sold.

BlackRock Fund Advisors first reported a position in GLMD in Q4 2015 and held it in 1 quarter. The position peaked at $7K in Q4 2015. 18 funds tracked by Wall St. Rank hold GLMD as of Q1 2016.

  • BlackRock Fund Advisors reported no remaining Galmed Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
  • BlackRock Fund Advisors sold 5 Galmed Pharmaceuticals shares in Q1 2016, an estimated $7K.
  • BlackRock Fund Advisors first reported a position in Galmed Pharmaceuticals in Q4 2015 and held it in 1 quarter.
  • BlackRock Fund Advisors's Galmed Pharmaceuticals position peaked at $7K in Q4 2015.
  • 18 funds tracked by Wall St. Rank held Galmed Pharmaceuticals as of Q1 2016.

Based on BlackRock Fund Advisors's 13F filing for Q1 2016, filed 10 May 2016.